Tags : Light-chain Amyloidosis

Genmab Reports Results of Daratumumab Based Combination Therapy in P-III

Tuba Khan May 29, 2020

Shots: The P-III ANDROMEDA (AMY3001) study involves assessing of Daratumumab (SC) + cyclophosphamide + bortezomib + dexamethasone (CyBorD) vs CyBorD as monothx. in 388 patients newly diagnosed with AL amyloidosis, […]readmore

Tags : Light-chain Amyloidosis

Genmab Reports Results of Daratumumab Based Combination Therapy in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Light-chain Amyloidosis

Genmab Reports Results of Daratumumab Based Combination Therapy in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company